TrialClinical trialPHN-02692024-04-15 19:00 CT
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists a randomized, double-blind crossover trial of elamipretide in subjects with Barth syndrome as completed. The trial evaluated safety, tolerability, and efficacy, but the provided excerpt contains no results.
01—Key points
- 01The registry lists the trial status as completed.
- 02The study used a randomized, double-blind crossover design.
- 03No participant counts or outcome data are provided.
Why it matters Editorial
The listing documents clinical evaluation of elamipretide for Barth syndrome but does not establish its safety or efficacy.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
02—Related news
Trial
PHN-0262
2026-10-26 19:00 CT
An Intermediate Size Expanded Access Protocol of Elamipretide
ClinicalTrials.gov: elamipretide
Trial
PHN-0263
2026-09-16 19:00 CT
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
ClinicalTrials.gov: elamipretide
Trial
PHN-0264
2026-09-16 19:00 CT
Trial
PHN-0265
2025-12-11 18:00 CT
FRDA Investigator Initiated Study (IIS) With Elamipretide
ClinicalTrials.gov: elamipretide
Trial
PHN-0266
2025-12-09 18:00 CT
Study of Healthy Aging and Physical Function With Elamipretide
ClinicalTrials.gov: elamipretide